Join Now

Category Archives: BioUtah News

Fluidx Medical Announces First Tumor Patient Treated in Prospective, Multinational Trial

Embolic device designed for improved preparation, delivery, and deep vessel filling for treating tumors and other interventional oncology uses.

| Tagged | Comments Off on Fluidx Medical Announces First Tumor Patient Treated in Prospective, Multinational Trial

EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA

EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA

| Tagged | Comments Off on EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA

Merit Medical’s WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients

WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial

| Tagged | Comments Off on Merit Medical’s WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients

BioUtah Award Winners and Utah Rare Disease Advisory Council Take Center Stage at Utah Life Sciences Innovation Caucus

More than a dozen Utah legislators on Wednesday, November 20, held a breakfast meeting of the Utah Life Sciences Innovation Caucus (ULSIC) at the state capitol.

Also posted in Policy News | | Comments Off on BioUtah Award Winners and Utah Rare Disease Advisory Council Take Center Stage at Utah Life Sciences Innovation Caucus

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

| Tagged | Comments Off on Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor types

| Tagged | Comments Off on Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

EVŌQ Nano Expands Antimicrobial Medical Device Platform, Demonstrates Efficacy Across Multiple Device Applications

Four Integration Methods Aim to Combat Healthcare-Associated Infections & Improve Device Performance

| Tagged | Comments Off on EVŌQ Nano Expands Antimicrobial Medical Device Platform, Demonstrates Efficacy Across Multiple Device Applications

SINTX TECHNOLOGIES AND NED MEDICAL PARTNER TO ADVANCE CUTTING-EDGE CERAMIC MICROSPHERE MEDICAL DEVICES FOR CANCER TREATMENT

SINTX TECHNOLOGIES AND NED MEDICAL PARTNER TO ADVANCE CUTTING-EDGE CERAMIC MICROSPHERE MEDICAL DEVICES FOR CANCER TREATMENT

| Tagged | Comments Off on SINTX TECHNOLOGIES AND NED MEDICAL PARTNER TO ADVANCE CUTTING-EDGE CERAMIC MICROSPHERE MEDICAL DEVICES FOR CANCER TREATMENT

First of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities

First of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities

| Tagged | Comments Off on First of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities

Seek Labs Announces Partnership with Cerbrec to Accelerate Diagnostic and Therapeutic Innovation with Graphbook Software

Seek Labs Announces Partnership with Cerbrec

| Tagged | Comments Off on Seek Labs Announces Partnership with Cerbrec to Accelerate Diagnostic and Therapeutic Innovation with Graphbook Software

Recursion and Exscientia Shareholders Approve the Proposed Combination

Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close

| Tagged | Comments Off on Recursion and Exscientia Shareholders Approve the Proposed Combination

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new “gold standard” outperforming CellProfiler

| Tagged | Comments Off on Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden